115 related articles for article (PubMed ID: 8882949)
1. Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia.
Leopold LH; Shore SK; Reddy EP
Leuk Lymphoma; 1996 Aug; 22(5-6):365-73. PubMed ID: 8882949
[TBL] [Abstract][Full Text] [Related]
2. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
[TBL] [Abstract][Full Text] [Related]
3. Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias.
Leopold LH; Shore SK; Newkirk TA; Reddy RM; Reddy EP
Blood; 1995 Apr; 85(8):2162-70. PubMed ID: 7718886
[TBL] [Abstract][Full Text] [Related]
4. Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia.
Wright L; Wilson SB; Milliken S; Biggs J; Kearney P
Exp Hematol; 1993 Dec; 21(13):1714-8. PubMed ID: 8243570
[TBL] [Abstract][Full Text] [Related]
5. An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.
Liu JH; Wu SC; Chen WS; Yen CC; Yang MH; Tsai YC; Chen PM
Biochem Biophys Res Commun; 2004 Jun; 318(3):764-72. PubMed ID: 15144904
[TBL] [Abstract][Full Text] [Related]
6. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line.
Snyder DS; Wu Y; Wang JL; Rossi JJ; Swiderski P; Kaplan BE; Forman SJ
Blood; 1993 Jul; 82(2):600-5. PubMed ID: 8329715
[TBL] [Abstract][Full Text] [Related]
7. Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs.
Lange W; Daskalakis M; Finke J; Dölken G
FEBS Lett; 1994 Jan; 338(2):175-8. PubMed ID: 8307177
[TBL] [Abstract][Full Text] [Related]
8. Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to non-contiguous sequences.
Pachuk CJ; Yoon K; Moelling K; Coney LR
Nucleic Acids Res; 1994 Feb; 22(3):301-7. PubMed ID: 8127665
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.
Kuwabara T; Warashina M; Tanabe T; Tani K; Asano S; Taira K
Nucleic Acids Res; 1997 Aug; 25(15):3074-81. PubMed ID: 9224607
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line.
Wright LA; Milliken S; Biggs JC; Kearney P
Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):15-23. PubMed ID: 9512092
[TBL] [Abstract][Full Text] [Related]
11. Improved specificity of ribozyme-mediated cleavage of bcr-abl mRNA.
Kearney P; Wright LA; Milliken S; Biggs JC
Exp Hematol; 1995 Aug; 23(9):986-9. PubMed ID: 7543419
[TBL] [Abstract][Full Text] [Related]
12. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity.
Shore SK; Nabissa PM; Reddy EP
Oncogene; 1993 Nov; 8(11):3183-8. PubMed ID: 8414522
[TBL] [Abstract][Full Text] [Related]
13. Ribozyme mediated therapy for chronic myelogenous leukemia.
Leopold LH; Shore SK; Newkirk T; Mangan K; Reddy EP
Prog Clin Biol Res; 1994; 389():175-82. PubMed ID: 7700900
[No Abstract] [Full Text] [Related]
14. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
[TBL] [Abstract][Full Text] [Related]
15. Investigating and improving the specificity of ribozymes directed against the bcr-abl translocation.
James H; Mills K; Gibson I
Leukemia; 1996 Jun; 10(6):1054-64. PubMed ID: 8667643
[TBL] [Abstract][Full Text] [Related]
16. A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo.
Kuwabara T; Warashina M; Tanabe T; Tani K; Asano S; Taira K
Mol Cell; 1998 Nov; 2(5):617-27. PubMed ID: 9844634
[TBL] [Abstract][Full Text] [Related]
17. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
Kronenwett R; Haas R; Sczakiel G
J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
[TBL] [Abstract][Full Text] [Related]
18. Specificity of ribozymes against the bcr-abl mRNAs in vitro.
James HA; Twomey CM; Mills KI; Gibson I
Biochem Soc Trans; 1996 Aug; 24(3):409S. PubMed ID: 8878953
[No Abstract] [Full Text] [Related]
19. In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA.
Lange W; Cantin EM; Finke J; Dölken G
Leukemia; 1993 Nov; 7(11):1786-94. PubMed ID: 8231247
[TBL] [Abstract][Full Text] [Related]
20. Comparison of activities between hammerhead ribozymes and DNA enzymes targeted to L6 BCR-ABL chimeric (b2a2) mRNA.
Warashina M; Kuwabara T; Taira K
Nucleic Acids Symp Ser; 1997; (37):213-4. PubMed ID: 9586075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
